Alpha-1 Antitrypsin Deficiency (AATD) is a rare genetic disorder caused by SERPINA1 gene mutations, leading to conditions like pulmonary emphysema and liver dysfunction. The AATD market is in its ...

Please provide your email address to receive an email when new articles are posted on . Direct-to-consumer testing, combined with clinical follow-up, helped identify patients with undiagnosed alpha-1 ...

Alpha-1 antitrypsin deficiency, AATD, is an inherited disease affecting the lung, liver, and, rarely, skin. Alpha-1 antitrypsin, AAT, is a protease inhibitor of the proteolytic enzyme elastase.

Wave Life Sciences (NASDAQ:WVE) is one of the 17 biotechnology stocks with more than 50% upside. As of the February 12 ...

Researchers at Saint Louis University's School of Medicine, in collaboration with Arrowhead Pharmaceuticals and Takeda Pharmaceuticals, report the first effective drug to treat a rare, genetic liver ...

Austin, Texas, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Alpha-1 Antitrypsin Deficiency Market Size & Growth Analysis: According to SNS Insider, The Alpha-1 Antitrypsin Deficiency Market was valued at USD ...

PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that the first patient has been dosed in Takeda’s (TSE:4502/NYSE:TAK) Phase 3 REDWOOD clinical study of ...

New research shows that people diagnosed with a genetic condition, called alpha-1 antitrypsin deficiency (AATD), are far more likely to stop smoking and therefore prevent the development of lung ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Augmentation therapy increased survival in patients with ...

CAMBRIDGE, Mass., Dec. 12, 2020 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), is presenting the first demonstration of physiological protein levels of human alpha-1 antitrypsin (AAT) ...